BioStock: Spago Nanomedical reports advancement

Lund-based Spago Nanomedical recently published its financial statements for 2022, where the company reports advancement within its projects with the upcoming start of clinical studies in Tumorad and the initiation of the company's first clinical phase II study with SpagoPix. BioStock reached out to CEO Mats Hansen to hear more about the company's ambitions for 2023.

Read the interview with Spago Nanomedical's CEO Mats Hansen at biostock.se:

https://www.biostock.se/en/2023/02/spago-nanomedical-reports-advancement/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/